SPC365

Functional Capacity assessment for Tafamidis treatment in Cardiac Amyloidosis patients

Session: SESSÃO DE POSTERS 04 - AMILOIDOSE E AORTA
Speaker: Bruno Miguel Delgado

Congress: CPC 2025
Topic: M. Cardiovascular Nursing
Theme: 32. Cardiovascular Nursing
Subtheme: 32.3 Cardiovascular Nursing - Other
Session Type: Cartazes
FP Number: ---
Authors: Bruno Delgado; Celia Neto; Ana Pereira
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Background: </span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Cardiac amyloidosis is a disease characterized by abnormal deposition of amyloid proteins in the myocardium, causing progressive cardiac dysfunction. This deposition of amyloid substance can lead to symptoms such as dyspnea, activity intolerance, oedema and dysrhythmias.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">There are different types of cardiac amyloidosis, depending on the type of amyloid protein involved. The two most common types are transthyretin-associated cardiac amyloidosis (ATTR) and light chain-associated cardiac amyloidosis (LDA).</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Tafamidis is a drug that has been used in the treatment of cardiac amyloidosis, being a stabilizer of amyloid transthyretin (TTR), allowing to reduce the formation of amyloid substance and the progression of the disease. </span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">The six-minute walk test is a test used to assess the functional capacity of patients with cardiac amyloidosis before starting to take tafamidis and as a follow-up test to assess the functional evolution of the patient under pharmacological treatment. This test can provide information about exercise tolerance and disease progression over time.</span></span></span></span></p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Aim: </span></span></span></span></p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">To evaluate functional capacity of cardiac amyloidosis patients before starting Tafamidis treatment alongside with home-based cardiac rehabilitation program</span></span></span></span></p>

<p>&nbsp;</p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Methods:</span></span></span></span></p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">The prescription of tafamidis requires an extensive evaluation of several parameters, being one of those the functional capacity of the patient. In this study the functional capacity was assessed by the 6-minute walking test, according to the ATS guidelines. Patients were consecutively recruited for treatment and prior to this, a 6-minute walking teste was performed. After starting the medication and according to the functional capacity, a home-based cardiac rehabilitation program was also recommended. At one year, a follow-up will be performed. </span></span></span></span></p>

<p>&nbsp;</p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Results:</span></span></span></span></p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">A total of 28 patients were evaluated, being 2 females. The mean age was 78 years old and 52% of the patients presented a reduction of left ventricular ejection fraction, being the mean score of ejection fraction 42%. Patients walked a mean distance of 362meters at the six-minute walking test. The cut off distance to be selected for medication is 100meters, and all of the patients walked more than that. Regarding the pro-BNP values, patients presented a mean value of 2635. To all of them a home-based cardiac rehabilitation program was prescribed. </span></span></span></span></p>

<p>&nbsp;</p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">Conclusion</span></span></span></span></p>

<p><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:13.5pt"><span style="font-family:Montserrat">All the selected patients were elected for treatment. At one year follow up another functional evaluation will be performed and several contacts will be done in order to accompany the evolution of the patients. </span></span></span></span></p>